Cresco Labs (CRLBF) Short term Debt (2020 - 2026)

Cresco Labs' (CRLBF) quarterly Short term Debt came in at $10.9 million in Q1 2026, up 0.69% on a QoQ basis from $10.8 million in Q4 2025.

Cresco Labs (CRLBF) Short term Debt (2020 - 2026) Analysis & Trends

Cresco Labs (CRLBF) has 7 years of Short term Debt data on file, last reported at $10.9 million in Q1 2026.

Quarterly Short term Debt changed N/A year-over-year to $10.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.9 million (changed N/A YoY) and the FY2025 annual result came in at $10.8 million, down 9.64% from the prior year.
Short term Debt climbed to $10.9 million in Q1 2026, from $10.8 million in the prior quarter.
In the past five years, Short term Debt ranged from a high of $11.9 million in Q4 2024 to a low of $10.8 million in Q4 2025.
A 5-year average of $11.3 million and a median of $11.0 million in 2022 frame the typical range for Short term Debt.
Annual changes were most pronounced in 2022 — Short term Debt slumped 44.92% — and 2023, when it rose 7.66%.
Tracing CRLBF's Short term Debt over 5 years: stood at $11.0 million in 2022, then grew by 7.66% to $11.8 million in 2023, then advanced by 0.99% to $11.9 million in 2024, then fell by 9.64% to $10.8 million in 2025, then rose by 0.69% to $10.9 million in 2026.
The last three Short term Debt figures came in at $10.9 million (Q1 2026), $10.8 million (Q4 2025), and $11.9 million (Q4 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-
10	Cresco Labs	290.46 Mn	226.34 Mn	86.95 Mn

Download Data